John Thurston, MD
Family Medicine · Worland, WYNPI 1144296245
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$812
- Lilly USA, LLC$675
- Merck$624
- Novo Nordisk$405
- Amgen$350
- Novartis$272
- plus $969 from 22 others
What the payments were for
- Food & beverage$4,094100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $812 |
| Lilly USA, LLC | 47 | $675 |
| Merck | 38 | $624 |
| Novo Nordisk | 30 | $405 |
| Amgen | 23 | $350 |
| Novartis | 18 | $272 |
| AbbVie(2 entities) | 7 | $155 |
| Sanofi-aventis U.S. LLC | 6 | $120 |
| Grifols USA, LLC | 4 | $111 |
| Pfizer | 4 | $76 |
| Bayer | 4 | $62 |
| Harmony Biosciences LLC | 3 | $55 |
| GSK | 3 | $44 |
| Johnson & Johnson | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Boehringer Ingelheim | 2 | $32 |
| Radius Health, Inc. | 2 | $29 |
| Eisai Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Corcept Therapeutics | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 2 | $21 |
| Stryker | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Convatec Inc. | 1 | $15 |
| Edwards Lifesciences | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Bioventus LLC | 1 | $12 |
How this compares
$4,106 in reported general payments places this provider in the 95th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $140,224 |
| EliquisApixaban | 152 | $105,515 |
| JardianceEmpagliflozin | 97 | $75,747 |
| FarxigaDapagliflozin Propanediol | 61 | $41,138 |
| EntrestoSacubitril/Valsartan | 55 | $40,807 |
| TrulicityDulaglutide | 35 | $38,132 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $30,716 |
| Repatha SureclickEvolocumab | 54 | $28,990 |
| MounjaroTirzepatide | 27 | $25,588 |
| XareltoRivaroxaban | 34 | $22,273 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $19,859 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $17,791 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $15,759 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $15,359 |
| JanuviaSitagliptin Phosphate | 18 | $14,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $405 | $140,224127 claims |
| PfizerEliquis | $76 | $105,515152 claims |
| Boehringer IngelheimJardiance | $32 | $75,74797 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $812 | $64,911101 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $675 | $63,72062 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $44 | $45,66298 claims |
| NovartisEntresto | $272 | $40,80755 claims |
| Johnson & JohnsonXarelto, Invokana | $42 | $31,58648 claims |
| MerckJanuvia, Dulera | $624 | $19,89035 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $120 | $9,76512 claims |
| AbbVieSavella | $155 | $8,89617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Worland
- Joseph SchoeberCasper$176K
- James McLennanCasper$13K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Jonathon MedinaCheyenne$6K
- Carol FischerCheyenne$6K
- Louis RoussalisCasper$5K
- Joseph MickelsonCasper$5K
- Jacob JohnsonRock Springs$5K
- Douglas EdgrenCheyenne$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.